Bometase alfa for bleeding in acquired hemophilia A
Part of Blood & lymphatic clinical trials.
This study tests an investigational drug called Bometase Alfa to help control bleeding in people with acquired hemophilia A, a rare condition where the immune system attacks a clotting protein. If you have active bleeding from this condition, this treatment might help stop it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have acquired hemophilia A, confirmed by specific blood tests showing low factor VIII and a positive inhibitor.
- You are currently experiencing significant bleeding, such as muscle bleeds, bruising, blood in urine or stool, or bleeding after childbirth or surgery.
- You are not pregnant or breastfeeding.
- You can attend follow-up visits for at least 30 days and agree to the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is studying a medication called susoctocog alfa for people with acquired hemophilia A, a bleeding disorder. It aims to understand how well the treatment works and how it is being used.
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
This early-phase study tests an FVIII gene therapy to help your body make more of the missing clotting factor in hemophilia A. It’s aimed at adults with severe low FVIII levels who have already used FVIII replacement products for a long time and have not developed an immune blocker (an inhibitor).
This trial tests a gene therapy to help your body produce more of the clotting protein (factor VIII) it's missing. It may reduce or stop the need for regular factor infusions.
This Phase 1/2 study tests ZS801, a gene-related treatment, to see how safe it is and whether it helps prevent bleeding in adults with hemophilia B. You may be considered if you’ve had frequent bleeds or joint problems and meet several lab and health requirements.
This trial studies whether SEVENFACT® can reduce bleeding episodes in people with hemophilia A or B who have inhibitors (proteins that make standard treatments less effective). It also tests how well people can track bleeding and medicine use during the study.
Hear when a new Acquired Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.